Literature DB >> 27408081

Prostate Cancer - What's New?

D Doddamani1, A Kayastha2.   

Abstract

Research has shown that prostate specific antigen (PSA) is a tumour marker for diagnosis of cancer prostate with significant prognostic value. Screening studies in North America and Europe have revealed that carcinoma prostate is common. Early detection and treatment improves the quality of life besides preventing deaths due to metastatic prostate cancer. Radical prostatectomy and laparoscopic radical prostatectomy has become the standard treatment for localized prostate cancer in all major uro-oncological centres resulting in reduced mortality. Magnetic resonance imaging and positron emission tomography have helped in detecting local and distant spread of cancer prostate. Revised approach to reduce occurrence of prostate cancer by the use of 5 alpha reductase inhibitors like finasteride and dietary supplements has been instituted. The World Health Organisation (WHO) has recommended lifestyle changes to promote men's health and reduce the incidence of prostate cancer.

Entities:  

Keywords:  Prostate cancer; Prostate specific antigen; Radical prostatectomy; Watchful waiting

Year:  2011        PMID: 27408081      PMCID: PMC4921738          DOI: 10.1016/S0377-1237(08)80149-9

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  21 in total

1.  Proceedings from the Prostate Cancer Global Opinion Leaders' Workshop. 28-29 January 2004, Paris, France.

Authors: 
Journal:  BJU Int       Date:  2004-12       Impact factor: 5.588

Review 2.  Future therapies in hormone-refractory prostate cancer.

Authors:  Matthew R Smith; Joel B Nelson
Journal:  Urology       Date:  2005-05       Impact factor: 2.649

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  High 10-year survival rate in patients with early, untreated prostatic cancer.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; L Holmberg; U B Krusemo
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

5.  Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.

Authors:  Shinji Urakami; Tateki Yoshino; Nobuyuki Kikuno; Shin Imai; Satoshi Honda; Tatuaki Yoneda; Hirofumi Kishi; Kazushi Shigeno; Hiroaki Shiina; Mikio Igawa
Journal:  Urology       Date:  2005-03       Impact factor: 2.649

6.  Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies.

Authors:  Scott M Gilbert; Christina B Cavallo; Hillel Kahane; Franklin C Lowe
Journal:  Urology       Date:  2005-03       Impact factor: 2.649

7.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.

Authors:  Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

Review 8.  Update on chemoprevention of prostate cancer.

Authors:  Eric A Klein; Ian M Thompson
Journal:  Curr Opin Urol       Date:  2004-05       Impact factor: 2.309

Review 9.  Update on hormone-refractory prostate cancer.

Authors:  Karl M Kasamon; Nancy A Dawson
Journal:  Curr Opin Urol       Date:  2004-05       Impact factor: 2.309

Review 10.  What's new in the treatment of advanced prostate cancer?

Authors:  C N Sternberg
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.